Jubilant Pharmova Limited has informed the Exchange regarding a press release dated May 16, 2025, titled "Press Release and presentation on the financials and operational performance of the Company for the fourth quarter and the financial year ended March 31, 2025".
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Pharmova reported FY25 revenue of Rs. 7,235 Cr, up 8% year-on-year, driven by growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew 24% to Rs. 1,230 Cr with margins expanding by 220 basis points to 16.9%. Reported PAT jumped 1,050% to Rs. 836 Cr, while normalised PAT (adjusted for exceptional items) grew 112% to Rs. 415 Cr. The company reduced Net Debt/EBITDA from 2.5x to 1.1x through a voluntary debt prepayment of USD 125 million. The Board proposed a dividend of Rs. 5 per share. Key segment highlights include CDMO Sterile Injectables EBITDA surging 52%, CRDMO Drug Discovery revenue up 27%, and Generics achieving profitability for the first time at 3% EBITDA margin.
Strong broad-based growth, margin expansion, and significant deleveraging signal healthy operational momentum and are positive for shareholders. The proposed dividend and progress toward Vision 2030 targets (doubling revenue, 23-25% EBITDA margins, zero net debt) reinforce confidence, though Radiopharmacy margins compressed due to competitive intensity and a global Technetium shortage.